DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The National Vaccine Program Office (NVPO), of the Centers for Disease Control and Prevention (CDC), Announces the Following Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Workshop on Aluminum in Vaccines.

Times and Dates: 9 a.m.–9 p.m., May 11, 2000; 9 a.m.–2 p.m., May 12, 2000.

Place: Hilton Caribe Hotel, San Juan, Puerto Rico.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 500 people.

Purpose: The Workshop will discuss the role of aluminum in vaccines.

Matters To Be Discussed: Agenda items will include presentations and discussion including: the role of adjuvants in vaccines; and, the pharmacokinetics, toxicology, health guidance values, immunology, and possible adverse events associated with aluminum in vaccines.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Sandra Browning and/or Lena Kombo, NVPO, CDC, 1600 Clifton Road, NE, M/S D66, Atlanta, Georgia 30333, telephone 404/687–6672. You may also visit the NVPO website for additional information: www.cdc.gov/od/nvpo/calendar.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and ATSDR.

Dated: March 13, 2000.

Carolyn Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 00–6799 Filed 3–17–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Breast and Cervical Cancer Early Detection and Control Advisory Committee Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Breast and Cervical Cancer Early Detection and Control Advisory Committee.

Times and Dates: 1 p.m.–4:45 p.m., May 9, 2000; 9 a.m.–5 p.m., May 10, 2000.

Place: The Wyndham Hotel, (Midtown), 10th Street, Atlanta, Georgia, 30311, telephone: 404/873–4800.

Status: Open to the public, limited only by the space available.

Purpose: This committee is charged with providing advice and guidance to the Secretary, the Assistant Secretary for Health, and the Director of CDC, regarding the need for early detection and control of breast and cervical cancer and to evaluate the Department's current breast and cervical cancer early detection and control activities.

Matters to be Discussed: The discussion will primarily focus on the role of Professional Education and Training in the National Breast and Cervical Cancer Early Detection Program. Additional items to be discussed include the (1) termination date of the committee; and (2) progress made towards the 1990 Strategic Plan.

Members of the public who wish to make a brief oral presentation at the meeting should contact Ms. Tamikio Bohler, 770/488–3199 or Ms. Cecilia Nkabinde, 770/488–3199 by 4 p.m. on April 13, 2000, to have time reserved on the agenda. Each individual or group making an oral presentation will be limited to 5 minutes. The request should identify the name of the individual who will make the presentation and an outline of the issues to be addressed. At least 25 copies of the presentation and 25 copies of the visual aids used at the meeting are to be given to Ms. Bohler, no later than the time of the presentation for distribution to the Committee and the interested public.

Contact Person for Additional Information: Tamikio Bohler, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, NE, M/S K–64, Atlanta, Georgia 30341–3724, telephone 770/488–3199.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: March 14, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 00–6798 Filed 3–17–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Clinical Laboratory Improvement Advisory Committee (CLIAC): Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).

Times And Dates: 8:30–5 p.m., April 5, 2000; 8:30 a.m.–3:30 p.m., April 6, 2000.

Place: CDC, Koger Center, Williams Building, Conference Rooms 1802 and 1805, 2877 Brandywine Road, Atlanta, Georgia 30341.

Status: Open to the public, limited only by the space available. The meeting rooms accommodate approximately 85 people.

Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

Matters To Be Discussed: The agenda will include discussion on specimens and test systems not currently regulated under Clinical Laboratory Improvement Amendments (CLIA), current and future research related to CLIA, and introduction to proficiency testing issues.

The Committee solicits oral and written testimony on all three areas cited in the matters to be discussed above. Requests to make an oral presentation should be submitted in writing to the contact person listed below by close of business, March 29, 2000. All requests to make oral comments should contain the name, address, telephone number, and organizational affiliation of the presenter. Written comments should not exceed five single-spaced typed pages in length and should be received by the contact person listed below by close of business, March 29, 2000.

Agenda items are subject to change as priorities dictate.

Contact Person for Additional Information: Devery Howerton, Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, Mailstop F–11, Atlanta, Georgia 30341–3724, telephone 770/488–8044, FAX 770/488–8279.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and ATSDR.

Dated: March 14, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 00–6800 Filed 3–17–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98F–0568]

FMC Corp.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 8A4605) proposing that the food additive regulations be amended to provide for the safe use of sodium stearoyl lactylate as an emulsifier, stabilizer, and texturizer in salad dressings and soups.

FOR FURTHER INFORMATION CONTACT: Mary E. LaVecchia, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3072.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of July 27, 1998 (63 FR 40126), FDA announced that a food additive petition (FAP 8A4605) had been filed by FMC Corp., c/o Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001. The petition proposed to amend the food additive regulations in § 172.846 *Sodium stearoyl lactylate* (21 CFR 172.846) to provide for the expanded safe use of sodium stearoyl lactylate as an emulsifier, stabilizer, and texturizer in salad dressings and soups. FMC Corp. has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: February 23, 2000.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 00–6721 Filed 3–17–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N–0988]

Lilly Research Laboratories et al.; Withdrawal of Approval of 22 New Drug Applications and 36 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 22 new drug applications (NDA's) and 36 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

DATES: Effective April 19, 2000.

FOR FURTHER INFORMATION CONTACT: Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application No.	Drug	Applicant
NDA 6–139	Surfacaine (cyclomethycaine).	Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285.
NDA 6–904	Terfonyl (trisulfapyrimidines) Tablets and Oral Suspension.	Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543–4000.
NDA 9–357	Rau-Sed (reserpine) Tablets.	Do.
NDA 9–523	Tyzine 0.1% (tetrahydrozoline HCl).	Pfizer, Inc., 235 East 42d St., New York, NY 10017–5755.
NDA 9–941	Tyzine 0.05% (tetrahydrozoline HCl) Pediatric Nasal Drops.	Do.
NDA 10–520	Leritine (anileridine HCl) Injection	Merck & Co., Inc., P.O. Box 4, BLA–20, West Point, PA 19486.
NDA 11–028	Hydeltrasol (prednisolone sodium phosphate) Sterile Ophthalmic Ointment, 0.25%.	Do.
NDA 11–178	Isuprel (isoproterenol hydrochloride) Mistometer.	Sanofi Winthrop, Inc., 90 Park Ave., New York, NY 10016–1389.
NDA 11–602	Kenalog (triamcinolone acetonide) Lotion.	Bristol-Myers Squibb Co.
NDA 12–335	Forhistal (dimethindene maleate) Tablets.	Novartis Pharmaceuticals Corp., 59 Route 10, East Hanover, NJ 07936–1080.
NDA 12–337	Forhistal (dimethindene maleate) Syrup.	Do.
NDA 12–338	Forhistal (dimethindene maleate) Pediatric Drops.	Do.
NDA 16–755	Diapid (Lypressin Nasal Solution USP) Nasal Spray.	Novartis Pharmaceuticals Corp.
NDA 16–990	Intal (Cromolyn Sodium for Inhalation USP) Capsules.	Rhone-Poulenc Rorer Pharmaceuticals, Inc., 500 Arcola Rd., P.O. Box 1200, Collegeville, PA 19426–0107.
NDA 17–605	Xylo-Pfan (Xylose USP) Powder.	Savage Laboratories, 60 Baylis Rd., Melville, NY 11747.
NDA 19–215	FEMSTAT (butoconazole nitrate) 2% Vaginal Cream (prescription).	Hoffmann-La Roche, Inc., 340 Kingsland St., Nutley, NJ 07110–1199.
NDA 19–359	FEMSTAT (butoconazole nitrate) Suppositories, 100 milligrams (mg).	Do.